The highest dose level of HCQ (1200 mg daily) correlated with clinical benefit in nine out of 22 patients with refractory B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) wild-type melanoma [57]. Here, BRAF is linked to melanoma.